Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery. The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.
View Top Employees from Memo Therapeutics AGWebsite | http://www.memo-therapeutics.com |
Revenue | $5 million |
Funding | $18 million |
Employees | 26 (14 on RocketReach) |
Founded | 2012 |
Address | Wagistrasse 27, Schlieren, Zurich 8952, CH |
Phone | +41 44 515 91 40 |
Technologies |
JavaScript,
HTML,
PHP
+15 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Discovery Tools (Healthcare), Therapeutic antibodies, Business Services, Biotechnology, Infectious disease, Human antibodies, Antibody repertoire, antibodyome, High throughput, single B cell, Antibody discovery |
SIC | SIC Code 28 Companies, SIC Code 80 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541711 Companies, NAICS Code 5417 Companies |
Looking for a particular Memo Therapeutics AG employee's phone or email?
The Memo Therapeutics AG annual revenue was $5 million in 2024.
Lars Spenger is the Head Of Finance of Memo Therapeutics AG.
14 people are employed at Memo Therapeutics AG.
Memo Therapeutics AG is based in Schlieren, Zurich.
The NAICS codes for Memo Therapeutics AG are [541, 54171, 54, 541711, 5417].
The SIC codes for Memo Therapeutics AG are [28, 80, 283].